GLI-antagonist 58 and 61 (GANT 58 and GANT 61) [102] are small molecules that have been widely used in preclinical cancer models, where they display cytotoxic activity [103], induce apoptosis [104], and reduce NF-κB activity [105]. The gene discussed is GLI1; the disease is cancer.